Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sana Biotechnology, Inc. - Common Stock (NQ:SANA)

1.655 +0.155 (+10.33%)
Streaming Delayed Price Updated: 3:25 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sana Biotechnology, Inc. - Common Stock

< Previous 1 2 3 Next >
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
From Pomerantz LLP
Via GlobeNewswire
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
From Faruqi & Faruqi LLP
Via GlobeNewswire
Sana Biotechnology, Inc. Stockholder News: Robbins LLP Reminds Investors of the Class Action Lawsuit Against SANA
From Robbins LLP
Via GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
From Pomerantz LLP
Via GlobeNewswire
Rosen Law Firm Urges Sana Biotechnology, Inc. (NASDAQ: SANA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type 1 Diabetes, CS Diagnostics (OTCQB: CSDX) Cancer Therapy – CURR, TPET, PRSO, PNPN.V, EONR – Plus More Stocks Under $2 Inside See Now!
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at December 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at September 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at May and June 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sana Biotechnology, Inc
Via GlobeNewswire
Sana Biotechnology Announces Pricing of Upsized Public Offering
From Sana Biotechnology, Inc
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.